These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30662324)

  • 21. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.
    Ze E; Baek EK; Lee JJ; Chung HW; Ahn DG; Cho HJ; Kwon JC; Kim HJ; Lee H
    Clin Mol Hepatol; 2014 Sep; 20(3):267-73. PubMed ID: 25320730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study.
    Gu EL; Yu YQ; Wang JL; Ji YY; Ma XY; Xie Q; Pan HY; Wu SM; Li J; Chen CW; Xu XW; Wang YE; Yao GB; Wang H; Zhang WH
    World J Gastroenterol; 2015 Jan; 21(2):653-60. PubMed ID: 25605989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
    Park H; Park JY; Kim SU; Kim DY; Han KH; Chon CY; Ahn SH
    World J Gastroenterol; 2013; 19(43):7671-9. PubMed ID: 24431895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis.
    Lv GC; Yao JM; Yang YD; Zheng L; Sheng JF; Chen Y; Li LJ
    World J Gastroenterol; 2013 Jun; 19(22):3481-6. PubMed ID: 23801842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies.
    Kim HS; Yim HJ; Jang MK; Park JW; Suh SJ; Seo YS; Kim JH; Kim BH; Park SJ; Lee SH; Kim SG; Kim YS; Lee JI; Lee JW; Kim IH; Kim TY; Kim JW; Jeong SH; Jung YK; Park H; Hwang SG;
    World J Gastroenterol; 2015 Oct; 21(38):10874-82. PubMed ID: 26478678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B.
    Park MS; Kim BK; Kim KS; Kim JK; Kim SU; Park JY; Kim DY; Baartarkhuu O; Han KH; Chon CY; Ahn SH
    Clin Mol Hepatol; 2013 Mar; 19(1):29-35. PubMed ID: 23593607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
    Wang ML; Chen EQ; Zhang DM; Du LY; Yan LB; Zhou TY; Lei XZ; Lei BJ; Lu JJ; Liao J; Tang H
    J Viral Hepat; 2017 Nov; 24 Suppl 1():21-28. PubMed ID: 29082645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B.
    Jia HY; Ding F; Chen JY; Lian JS; Zhang YM; Zeng LY; Xiang DR; Yu L; Hu JH; Yu GD; Cai H; Lu YF; Zheng L; Li LJ; Yang YD
    World J Gastroenterol; 2015 Mar; 21(12):3657-62. PubMed ID: 25834334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.
    Kim HJ; Park SK; Yang HJ; Jung YS; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Choi KY
    Clin Mol Hepatol; 2016 Sep; 22(3):350-358. PubMed ID: 27729626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis.
    Liaw YF; Lee CM; Chien RN; Yeh CT
    J Viral Hepat; 2006 Apr; 13(4):250-5. PubMed ID: 16611191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
    Rapti I; Dimou E; Mitsoula P; Hadziyannis SJ
    Hepatology; 2007 Feb; 45(2):307-13. PubMed ID: 17256746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis.
    Liu F; Wang X; Wei F; Hu H; Zhang D; Hu P; Ren H
    Virol J; 2014 Mar; 11():59. PubMed ID: 24673792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance.
    Seo SY; Kim IH; Sohn JY; Lee S; Kim SH; Kim SW; Lee SO; Lee ST; Kim DG
    Intervirology; 2014; 57(1):8-16. PubMed ID: 23988634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients.
    Lai HW; Chang CC; Chen TH; Tsai MC; Chen TY; Lin CC
    J Formos Med Assoc; 2012 Aug; 111(8):439-44. PubMed ID: 22939662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.